Results
Verve Therapeutics Inc.
05/05/2025 | Press release | Distributed by Public on 05/05/2025 09:50
Nonclinical data demonstrate potent and precise inactivation of liver PCSK9 in vivo with clinical stage GalNAc base editing medicine, VERVE-102
Verve Therapeutics Inc. published this content on May 05, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 05, 2025 at 15:50 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io